at the Unified Patent Court, reached a peak in 2019 when Amgen enforced a PI judgment against Sanofi. In July of that year, the Regional Court Düsseldorf found Sanofi and Regeneron had infringed Amgen
specification may help illuminate the true focus of a claim, when analyzing patent eligibility, reliance on the specification must always yield to the claim language in identifying that focus.” Charge-Point, Inc.
upheld an important Bayer patent and thus overturned a first-instance decision. The dispute concerns Bayer’s patent EP 23 05 255, which expired in December 2022. The patent protects the compound of a
"framework" for regularly alerting the online marketplace about listings by counterfeiters in an effort to curtail illegal sales, the source said on condition of anonymity. Novo Nordisk is the sole patent
blockbuster eye drug Eylea violates its patent rights. Regeneron said in its lawsuit filed on Wednesday that Amgen infringed dozens of its patents. It asked the court to block Amgen's version of Eylea, which
issue. Is Teva liable for having executed the PI even though the legal status of the patent was still under review by the EPO Boards of Appeal? It is true that a patent holder that enforces a judgment
two other patents in the same family is final. For years, patent holder Illumina has been in dispute with Chinese biotechnology company MGI over various patents for DNA sequencing technology. Now the
Polygroup, which describes itself as the biggest global manufacturer of artificial Christmas trees in the world, had infringed Willis Electric’s patent related to lights for artificial Christmas trees.
Introduction: The China National Intellectual Property Administration(CNIPA), China’s top IP regulator, recently released on its website the "2023 China Patent Survey Report", which underscores the
Egg carton manufacturer Brødrene Hartmann has filed a lawsuit against Omnipac at the UPC, shortly before Easter. The Danish company accuses its German competitor of infringing a patent on a new type